Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, has been announced at Oracle CloudWorld the winner in the 2024 Oracle Partner Awards – Best in ...

Discover what crypto is and how it works. A cryptocurrency is a digital form of money. They are digital assets created to be used to pay for goods and services. Cryptocurrencies can be used as a ...

Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Jupiter Endovascular, Inc. announced that the first two patients were treated in the SPIRARE I trial of the Vertex pulmonary ...

This was the stock's second consecutive day of losses.